BPC 157 Peptide Shows Promise Against Deadly Abdominal Compartment Syndrome

Abdominal compartment syndrome (ACS) and intra-abdominal hypertension (IAH) represent life-threatening surgical emergencies characterized by progressive multiorgan failure affecting the brain, heart, lungs, liver, kidneys, and gastrointestinal tract. Despite their clinical significance, pharmacological management remains unsatisfactory. Current decompressive strategies such as open abdomen surgery carry their own morbidity, and available drug therapies generally work only prophylactically, address only one organ system, or are effective only in mild-to-moderate IAH grades.

This review, authored by researchers at the University of Zagreb's departments of Pharmacology, Pathology, and Surgery, systematically evaluates animal-study pharmacotherapy attempts for ACS/IAH and reframes the condition through the lens of cytoprotection theory—originally introduced by Robert and Szabo in the early 1980s for gastric protection. The authors argue that ACS/IAH represents a failure of cytoprotection at the cellular, epithelial, and endothelial levels, and that resolving it requires a pleiotropic agent capable of acting simultaneously on multiple failing systems.

The central therapeutic candidate reviewed is stable gastric pentadecapeptide BPC 157, a 15-amino-acid peptide native to human gastric juice that remains stable for over 24 hours in that environment. In rat models of grade III and grade IV IAH—induced by substantial air insufflation—BPC 157 was shown to rapidly counteract multiorgan damage during both the compression/ischemia phase and the decompression/reperfusion phase. Key mechanistic findings include activation of collateral blood-flow pathways, most notably direct azygos vein blood delivery, which the authors term a 'bypassing key.' This mechanism allowed restoration of reorganized circulation even when major vessels were occluded or functionally compromised.

BPC 157 therapy was associated with reversal of brain, cardiac, pulmonary, hepatic, renal, and gastrointestinal lesions and hemorrhages; resolution of portal and caval hypertension and aortic hypotension; reversal of peripheral and central (intracranial superior sagittal sinus) thrombosis; normalization of advanced Virchow triad conditions; and free radical scavenging with membrane stabilization. The peptide's modulatory effect on the nitric oxide (NO) system and its endothelial cytoprotective capacity are proposed as central to its vasomotor rescue effects.

In contrast, conventional pharmacological agents reviewed—not aligned with the cytoprotection framework—showed limited, single-organ, or prophylaxis-only efficacy. The authors conclude that BPC 157 represents a novel, therapeutically relevant cytoprotective mediator uniquely suited to the simultaneous multiorgan rescue required in ACS and IAH, and potentially applicable to other occlusion/occlusion-like syndromes.